Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104166 | 0.84 | RAB9A (0.46) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL1545508 | 0.83 | SOS1 (0.58) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL17788606 | 0.82 | NOTUM (0.57) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL10274629 | 0.80 | NOTUM (0.68) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL31686265 | 0.78 | NOTUM (0.59) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL28319063 | 0.77 | NOTUM (0.64) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL14552880 | 0.77 | RAB9A (0.67) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL17790250 | 0.77 | EPHX2 (0.53) | RAB9ASMN1; SMN2ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL1544128 | 0.77 | NOTUM (1.00) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL3396472 | 0.77 | NOTUM (0.68) | RAB9ASMN1; SMN2ALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RAB9A 1385/4885SMN1; SMN2 834/4885ALDH1A1 3223/4885 |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | RAB9A 3387/4885SMN1; SMN2 2947/4885ALDH1A1 1180/4885 |
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | RAB9A 1245/4885SMN1; SMN2 2362/4885ALDH1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.